Abstract: One disclosed example provides, enacted on a computing system, a method of resolving a device capability model (DCM) for a network connected device, the method comprising receiving, from the network connected device, an identifier of the DCM, based on the identifier received, determining whether the DCM is stored on the computing system, when the DCM is stored on the computing system, then retrieving the DCM from the computing system, when the DCM is not stored on the computing system, then retrieving the DCM from one or more of the network connected device and a DCM repository and storing the DCM on the computing system, receiving, from a software solution, an application programming interface (API) call to retrieve the DCM from the computing system, and in response to receiving the API call, returning the DCM to the software solution.

Abstract: One disclosed example provides, enacted on a computing system, a method of resolving a device capability model (DCM) for a network connected device, the method comprising receiving, from the network connected device, an identifier of the DCM, based on the identifier received, determining whether the DCM is stored on the computing system, when the DCM is stored on the computing system, then retrieving the DCM from the computing system, when the DCM is not stored on the computing system, then retrieving the DCM from one or more of the network connected device and a DCM repository and storing the DCM on the computing system, receiving, from a software solution, an application programming interface (API) call to retrieve the DCM from the computing system, and in response to receiving the API call, returning the DCM to the software solution.

Abstract: Disclosed are pharmaceutical compositions comprising ketamine and butamben. The compositions are useful in the treatment of pain.

Abstract: Topical compositions which include urea and an antimicrobial agent, particularly sulfacetamide or metronidazole, are described. Sulfacetamide compositions further including sulfur are also described. Methods for treating dermatological disorders using the compositions are also described.

Abstract: Topical compositions which include urea and an antimicrobial agent, particularly sulfacetamide, are described. Sulfacetamide compositions further including sulfur are also described. Methods for treating dermatological disorders using the compositions are also described.

Abstract: Methods of treating fungal conditions and onychomycosis are described which include administration of a safe and effective amount of urea in a topical formulation to an affected area on the skin or around a nail of a patient in need of treatment.

Abstract: Topical compositions which include urea and carbamide peroxide are described. Compositions having a pH in the acidic range, particularly in the range of about 2.5 to about 9 are also described. Methods for treating dermatological disorders using the composition are also described.

Abstract: This invention is directed to a novel solid matrixed controlled release, oral dosage form where the dosage form contains a therapeutically effective amount of a sulfonylurea or a salt or derivative thereof in the matrix. Further, the use of an aqueous alkalizing medium affords substantially complete bioavailability of the drug from the matrix of the tablet. The core tablets may optionally be coated with a coating material in the range of 2% to 10% with an enteric material or with a water insoluble material like ethyl cellulose.

Abstract: Described is a novel approach for treating actinic keratosis which involves the use of urea in a dermatological composition. The urea composition can be included in pre-treatment, treatment and post-treatment steps. Also described are novel topical compositions for the treatment step containing a combination of urea and a pharmaceutical agent for treating actinic keratosis, such as a caustic agent, 5-fluorouracil or a photosensitizing agent.

Abstract: Described are dermatological compositions for treating, protecting and re-epitheliazing cutaneous wounds and damaged skin, such compositions including about 21 to about 40% urea and trace amounts of zinc, copper and manganese in the form of their respective pharmaceutically acceptable salts.

Abstract: Topical compositions which include urea and benzoyl peroxide are described. Compositions having a pH in the acidic range, particularly in the range of about 4 to about 9 are also described. Methods for treating dermatological disorders using the composition are also described.

Abstract: The method of treating inflammatory skin conditions with compositions containing urea as the sole active ingredient is described. Although the mechanism by which urea acts as an anti-inflammatory agent is unclear, this very beneficial property has many useful applications in treating inflammatory dermatological conditions.

Abstract: A method of improving the effectiveness of topical anti-inflammatory drug(s) in the treatment of inflammatory conditions of the skin in humans is described which includes administration of an effective amount of urea in a topical formulation to an affected area of the skin of a patient either before, after or with the administration to such affected area of an effective amount of topical anti-inflammatory drug(s). Also described are topical compositions containing a combination of urea and an anti-inflammatory agent.

Abstract: A method of treating onychomycosis is described which includes administration of a topical formulation containing an effective amount of urea and an antioxidant to an infected area around a nail of a patient.

Abstract: Described is a method of treating the symptoms of non-constipated irritable bowel syndrome (IBS) and diarrhea-predominant IBS with methscopolamine bromide.

Abstract: Described are dermatological compositions for treating, protecting and re-epitheliazing cutaneous wounds and damaged skin, such compositions including about 21 to about 40% urea and trace amounts of zinc, copper and manganese in the form of their respective pharmaceutically acceptable salts.

Abstract: A method of treating onychomycosis is described which includes administration of a topical formulation containing an effective amount of urea and an antioxidant to an infected area around a nail of a patient.

Abstract: Enhanced dermatological compositions are described herein using from about 21 to about 40 wt-% urea with antioxidant skin protectants suitable for the treatment of icthyosis, xerosis, severely dry skin, dermatitis, eczema, debridement and tissue suffering and other similar skin conditions.

Abstract: A method of treating onychomycosis is described which includes administration of an effective amount of urea in a topical formulation to an infected area around a nail of a patient.

Abstract: This invention is directed to a novel solid matrixed controlled release, oral dosage form where the dosage form contains a therapeutically effective amount of a sulfonylurea or a salt or derivative thereof in the matrix. Further, the use of an aqueous alkalizing medium affords substantially complete bioavailability of the drug from the matrix of the tablet. The core tablets may optionally be coated with a coating material in the range of 2% to 10% with an enteric material or with a water insoluble material like ethyl cellulose.